Vestmark Advisory Solutions Inc. Trims Position in BioLife Solutions, Inc. (NASDAQ:BLFS)

Vestmark Advisory Solutions Inc. cut its position in BioLife Solutions, Inc. (NASDAQ:BLFS) by 25.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 9,065 shares of the medical equipment provider’s stock after selling 3,121 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in BioLife Solutions were worth $235,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Steward Partners Investment Advisory LLC bought a new position in shares of BioLife Solutions during the fourth quarter worth $26,000. Mark Sheptoff Financial Planning LLC bought a new position in shares of BioLife Solutions during the third quarter worth $28,000. Quest Partners LLC bought a new position in shares of BioLife Solutions during the third quarter worth $57,000. Smartleaf Asset Management LLC boosted its position in shares of BioLife Solutions by 27.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider’s stock worth $117,000 after acquiring an additional 950 shares during the last quarter. Finally, Summit Global Investments bought a new position in shares of BioLife Solutions during the third quarter worth $228,000. 93.24% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at BioLife Solutions

In related news, CFO Troy Wichterman sold 987 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $27.02, for a total value of $26,668.74. Following the transaction, the chief financial officer now owns 121,779 shares of the company’s stock, valued at $3,290,468.58. This represents a 0.80 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Aby J. Mathew sold 7,604 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $27.33, for a total value of $207,817.32. Following the completion of the transaction, the executive vice president now directly owns 276,315 shares in the company, valued at approximately $7,551,688.95. This trade represents a 2.68 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,978 shares of company stock worth $322,724. 2.20% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

BLFS has been the subject of a number of research reports. KeyCorp upped their target price on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Craig Hallum upped their target price on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Northland Securities upped their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 8th. TD Cowen increased their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Finally, Benchmark reiterated a “buy” rating and set a $30.00 price objective on shares of BioLife Solutions in a research report on Thursday, December 19th. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $29.86.

BioLife Solutions Price Performance

BLFS stock opened at $25.83 on Monday. The company has a fifty day simple moving average of $26.65 and a two-hundred day simple moving average of $25.49. The firm has a market capitalization of $1.21 billion, a P/E ratio of -24.37 and a beta of 2.04. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a 52 week low of $14.84 and a 52 week high of $29.55.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.32. The company had revenue of $22.71 million for the quarter, compared to the consensus estimate of $21.73 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. During the same period in the prior year, the firm posted ($0.21) EPS. Analysts anticipate that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.